What is Zacks Research’s Estimate for IRWD Q1 Earnings?

Ironwood Pharmaceuticals, Inc. (NASDAQ:IRWD) – Zacks Research raised their Q1 2026 earnings per share estimates for Ironwood Pharmaceuticals in a note issued to investors on Tuesday, January 20th. Zacks Research analyst Team now anticipates that the biotechnology company will post earnings per share of $0.07 for the quarter, up from their prior estimate of $0.01. Zacks Research currently has a “Strong-Buy” rating on the stock. The consensus estimate for Ironwood Pharmaceuticals’ current full-year earnings is $0.10 per share. Zacks Research also issued estimates for Ironwood Pharmaceuticals’ Q2 2026 earnings at $0.27 EPS, Q3 2026 earnings at $0.40 EPS, FY2026 earnings at $0.98 EPS, Q2 2027 earnings at $0.02 EPS and Q4 2027 earnings at ($0.02) EPS.

A number of other research firms have also commented on IRWD. Citigroup upgraded shares of Ironwood Pharmaceuticals from a “market perform” rating to an “outperform” rating in a report on Monday, January 5th. Citizens Jmp raised shares of Ironwood Pharmaceuticals from a “market perform” rating to a “market outperform” rating and set a $8.00 price objective for the company in a research note on Monday, January 5th. Craig Hallum raised Ironwood Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Monday, January 5th. Weiss Ratings restated a “sell (d)” rating on shares of Ironwood Pharmaceuticals in a report on Monday, December 29th. Finally, Wells Fargo & Company increased their price objective on Ironwood Pharmaceuticals from $3.00 to $5.00 and gave the stock an “equal weight” rating in a report on Monday, January 5th. Two research analysts have rated the stock with a Strong Buy rating, three have assigned a Buy rating, three have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $5.74.

Ironwood Pharmaceuticals Stock Performance

NASDAQ:IRWD opened at $5.31 on Thursday. The firm has a market cap of $863.83 million, a PE ratio of 33.19 and a beta of 0.18. Ironwood Pharmaceuticals has a fifty-two week low of $0.53 and a fifty-two week high of $5.78. The business has a 50 day moving average price of $3.69 and a 200-day moving average price of $2.13.

Ironwood Pharmaceuticals (NASDAQ:IRWD) last released its earnings results on Monday, November 10th. The biotechnology company reported $0.24 earnings per share for the quarter, beating analysts’ consensus estimates of $0.09 by $0.15. The company had revenue of $122.06 million during the quarter, compared to analyst estimates of $74.22 million. Ironwood Pharmaceuticals had a negative return on equity of 15.17% and a net margin of 8.70%.

Hedge Funds Weigh In On Ironwood Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the company. Integrated Wealth Concepts LLC grew its holdings in shares of Ironwood Pharmaceuticals by 21.4% during the third quarter. Integrated Wealth Concepts LLC now owns 19,295 shares of the biotechnology company’s stock valued at $25,000 after buying an additional 3,406 shares during the last quarter. Merit Financial Group LLC lifted its position in Ironwood Pharmaceuticals by 17.4% during the 3rd quarter. Merit Financial Group LLC now owns 48,879 shares of the biotechnology company’s stock worth $64,000 after acquiring an additional 7,232 shares during the period. Rhumbline Advisers grew its stake in Ironwood Pharmaceuticals by 3.5% during the 3rd quarter. Rhumbline Advisers now owns 223,229 shares of the biotechnology company’s stock valued at $292,000 after purchasing an additional 7,611 shares during the last quarter. Focus Partners Wealth increased its holdings in shares of Ironwood Pharmaceuticals by 29.3% in the third quarter. Focus Partners Wealth now owns 44,652 shares of the biotechnology company’s stock valued at $58,000 after purchasing an additional 10,105 shares during the period. Finally, BNP Paribas Financial Markets increased its holdings in shares of Ironwood Pharmaceuticals by 83.2% in the third quarter. BNP Paribas Financial Markets now owns 34,331 shares of the biotechnology company’s stock valued at $45,000 after purchasing an additional 15,594 shares during the period.

Ironwood Pharmaceuticals Company Profile

Ironwood Pharmaceuticals, Inc is a commercial?stage biotechnology company focused on the discovery, development and commercialization of medicines for gastrointestinal (GI) disorders. The company’s flagship product is linaclotide, marketed under the brand name LINZESS in the United States for the treatment of irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation (CIC). Through a strategic collaboration with Allergan (now part of AbbVie), Ironwood also commercializes linaclotide in select ex-U.S.